How are you approaching the use of neoadjuvant or adjuvant nab-paclitaxel given the improvement noted in disease free survival in the 2019 GBG 69–GeparSepto trial?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

For a patient with ER+, HER2-low leptomeningeal disease, but no other sites of metastatic disease, what treatments would you consider after trastuzumab deruxtecan?

Do you have any concerns about incorporating gedatolisib into the treatment landscape of HR+/HER2-, PIK3CA wild-type breast cancer (VIKTORIA-1)?

In which scenarios would you consider adjuvant CDK4/6 inhibitor use if there is only one ipsilateral axillary lymph node positive for microscopic disease?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.